RU2011110504A - Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды - Google Patents

Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды Download PDF

Info

Publication number
RU2011110504A
RU2011110504A RU2011110504/10A RU2011110504A RU2011110504A RU 2011110504 A RU2011110504 A RU 2011110504A RU 2011110504/10 A RU2011110504/10 A RU 2011110504/10A RU 2011110504 A RU2011110504 A RU 2011110504A RU 2011110504 A RU2011110504 A RU 2011110504A
Authority
RU
Russia
Prior art keywords
peptide
antigen
group
cancer
peptide according
Prior art date
Application number
RU2011110504/10A
Other languages
English (en)
Russian (ru)
Inventor
Такуя ЦУНОДА (JP)
Такуя Цунода
Рюдзи ОХСАВА (JP)
Рюдзи ОХСАВА
Сатико ЙОСИМУРА (JP)
Сатико Йосимура
Original Assignee
Онкотерапи Сайенс, Инк. (Jp)
Онкотерапи Сайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапи Сайенс, Инк. (Jp), Онкотерапи Сайенс, Инк. filed Critical Онкотерапи Сайенс, Инк. (Jp)
Publication of RU2011110504A publication Critical patent/RU2011110504A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K4/00Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122Ephrin Receptors [Eph]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4202Receptors, cell surface antigens or cell surface determinants
    • A61K40/422Ephrin Receptors [Eph]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2011110504/10A 2008-08-19 2009-08-14 Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды RU2011110504A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8997308P 2008-08-19 2008-08-19
US61/089,973 2008-08-19

Publications (1)

Publication Number Publication Date
RU2011110504A true RU2011110504A (ru) 2012-09-27

Family

ID=41707002

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011110504/10A RU2011110504A (ru) 2008-08-19 2009-08-14 Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды

Country Status (13)

Country Link
US (7) US20110280898A1 (enExample)
EP (1) EP2326718A4 (enExample)
JP (1) JP2012500001A (enExample)
KR (1) KR20110063456A (enExample)
CN (1) CN102186977A (enExample)
AU (1) AU2009283762A1 (enExample)
CA (1) CA2734515A1 (enExample)
IL (1) IL211131A0 (enExample)
MX (1) MX2011001880A (enExample)
RU (1) RU2011110504A (enExample)
SG (1) SG193214A1 (enExample)
TW (1) TW201008574A (enExample)
WO (1) WO2010021111A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2325305E (pt) * 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2009531273A (ja) * 2006-02-28 2009-09-03 オンコセラピー・サイエンス株式会社 抗EphA4抗体のエフェクター機能を用いて細胞を障害する方法
CN101432303A (zh) * 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗cdh3抗体的效应物功能来损伤细胞的方法
US20100009920A1 (en) * 2006-12-13 2010-01-14 Yusuke Nakamura Ttk as tumor marker and therapeutic target for lung cancer
WO2009016691A1 (en) * 2007-07-30 2009-02-05 Oncotherapy Science, Inc. Cancer associated gene ly6k
UA100127C2 (ru) * 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
CA2729403A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TWI543767B (zh) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗
JP5663790B2 (ja) 2008-10-22 2015-02-04 オンコセラピー・サイエンス株式会社 Rab6kifl/kif20aエピトープペプチドおよびそれを含むワクチン
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
ES2701626T3 (es) 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ect2胜肽及含此胜肽之疫苗
CN104040345A (zh) * 2011-12-23 2014-09-10 医疗研究局 血管紧张素ii受体的选择性配体
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
EP2872531A4 (en) * 2012-07-10 2016-04-06 Oncotherapy Science Inc LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
JP6259983B2 (ja) 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Th1細胞のKIF20Aエピトープペプチドおよびこれを含有するワクチン
BR112015013557B1 (pt) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2胜肽及含此胜肽之疫苗
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
SG11201700838VA (en) * 2014-08-04 2017-03-30 Oncotherapy Science Inc Urlc10-derived peptide and vaccine containing same
RU2753512C2 (ru) * 2014-09-08 2021-08-17 Нэшнл Кэнсер Сентер Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования
CA2969231C (en) 2014-12-03 2021-06-08 Verik Bio, Inc. Identification, selection and use of high curative potential t cell epitopes
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7751374B2 (ja) * 2017-03-03 2025-10-08 トレオス バイオ リミテッド ペプチドワクチン
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
AU2019334437A1 (en) 2018-09-04 2021-03-18 Treos Bio Limited Peptide vaccines
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3322314C2 (de) 1983-06-21 1986-01-02 Gebhard, Dietrich, 7502 Malsch Schaltungsanordnung für ein Zugfahrzeug
NZ217727A (en) 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
IL103928A0 (en) 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
WO1995028484A1 (en) 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
AU6795898A (en) 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1022286A4 (en) 1997-10-07 2003-04-09 Ono Pharmaceutical Co POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
EP1103561B1 (en) 1998-07-28 2006-04-19 Green Peptide Co., Ltd. Hla-a2 restraint tumor antigen peptide originating in sart-1
WO2001064835A2 (en) 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
AU6280300A (en) 1999-08-04 2001-03-05 Adelbert Bacher Isoprenoid biosynthesis
AU1220001A (en) 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
MXPA02008219A (es) 2000-02-23 2005-06-30 Epimmune Inc Peptidos que enlazan hla y sus usos.
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN1469926A (zh) 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US6830885B1 (en) 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
JP2005506033A (ja) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
US7033832B2 (en) 2000-10-13 2006-04-25 University Of Medicine And Dentistry Of New Jersey Endothelial cell—cell cohesion
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN100400099C (zh) 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
CA2444691A1 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
MXPA03011979A (es) 2001-06-18 2005-04-08 Eos Biotechnology Inc Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP1487857A4 (en) 2002-03-07 2006-08-09 Ludwig Inst Cancer Res BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
CA2499709A1 (en) 2002-06-19 2003-12-31 Yoichi Furukawa Method for diagnosis of colorectal tumors
EP1523577A2 (en) 2002-07-10 2005-04-20 Oncotherapy Science, Inc. Method for diagnosis of intestinal-type gastric tumors
FI116178B (fi) 2002-08-22 2005-09-30 Abb Oy Vaihtosuuntaajan lähtökuristinsovitelma
AU2003294217A1 (en) 2002-08-29 2004-05-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
AU2003253440A1 (en) 2002-08-30 2004-04-30 Japan As Represented By The President Of The University Of Tokyo Method of diagnosing ovarian endometriosis
CN1703524B (zh) 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
TW200413539A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003300680A1 (en) 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
WO2004058153A2 (en) 2002-12-20 2004-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
US7337154B2 (en) 2003-05-19 2008-02-26 Raytheon Company Method for solving the binary minimization problem and a variant thereof
WO2005001138A2 (en) 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7727714B2 (en) 2003-08-20 2010-06-01 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for clear cell renal cell carcinoma
EP1668354A2 (en) 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
EP1762094A4 (en) 2003-12-08 2007-11-14 Silicon Image Inc INTEGRATED ADDRESSING SCHEME FOR USE IN A SYSTEM WITH A TREE STRUCTURE
EP1730279A2 (en) 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
WO2005090572A2 (en) 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Compositions and methods for treating pancreatic cancer
WO2005097189A1 (ja) 2004-04-09 2005-10-20 Genecare Research Institute Co., Ltd. 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
WO2006038208A2 (en) 2004-07-12 2006-04-13 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2006055371A2 (en) 2004-11-16 2006-05-26 Alexion Pharmaceuticals, Inc. Functional screening of antibody libraries
CN100381460C (zh) 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
EP2011885B1 (en) 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
EP1859266A4 (en) 2005-02-24 2010-07-28 Cemines Inc COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES
PT2325305E (pt) * 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
CA2599875A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
CN100348614C (zh) 2005-06-03 2007-11-14 北京大学 一种肝癌-睾丸特异性抗原蛋白质和抗原肽
WO2007009181A1 (en) 2005-07-20 2007-01-25 Agriculture Victoria Services Pty Ltd Modification of flavonoid biosynthesis in plants
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP5150909B2 (ja) 2005-07-27 2013-02-27 オンコセラピー・サイエンス株式会社 食道癌を診断する方法
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
EP1915622A2 (en) 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP4803460B2 (ja) 2005-08-09 2011-10-26 学校法人 久留米大学 Hla−a24分子結合性扁平上皮癌抗原由来ペプチド
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
US20090263832A1 (en) 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
JP2009531273A (ja) 2006-02-28 2009-09-03 オンコセラピー・サイエンス株式会社 抗EphA4抗体のエフェクター機能を用いて細胞を障害する方法
CN101432303A (zh) 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗cdh3抗体的效应物功能来损伤细胞的方法
CN101467039B (zh) 2006-04-10 2013-11-06 健泰科生物技术公司 散乱蛋白pdz调节剂
US20100009920A1 (en) 2006-12-13 2010-01-14 Yusuke Nakamura Ttk as tumor marker and therapeutic target for lung cancer
WO2008102906A1 (en) 2007-02-20 2008-08-28 Oncotherapy Science, Inc. Hspc-hrpc transition genes
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
WO2009016691A1 (en) 2007-07-30 2009-02-05 Oncotherapy Science, Inc. Cancer associated gene ly6k
UA100127C2 (ru) 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI543767B (zh) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗
WO2011039289A1 (de) 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
US8623829B2 (en) 2014-01-07
SG193214A1 (en) 2013-09-30
US8759481B2 (en) 2014-06-24
EP2326718A1 (en) 2011-06-01
WO2010021111A1 (en) 2010-02-25
JP2012500001A (ja) 2012-01-05
US20110280898A1 (en) 2011-11-17
AU2009283762A1 (en) 2010-02-25
KR20110063456A (ko) 2011-06-10
MX2011001880A (es) 2011-03-29
US9067973B2 (en) 2015-06-30
EP2326718A4 (en) 2012-03-07
US20130189291A1 (en) 2013-07-25
US9284349B2 (en) 2016-03-15
US20140248300A1 (en) 2014-09-04
US20160200764A1 (en) 2016-07-14
US20140141027A1 (en) 2014-05-22
US20120321649A1 (en) 2012-12-20
CA2734515A1 (en) 2010-02-25
TW201008574A (en) 2010-03-01
CN102186977A (zh) 2011-09-14
US20100040641A1 (en) 2010-02-18
US8383590B2 (en) 2013-02-26
IL211131A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
JP2012500001A5 (enExample)
RU2009141595A (ru) Пептиды тем8 и содержащие их вакцины
JP2010506826A5 (enExample)
JP2008530975A5 (enExample)
RU2011138160A (ru) Пептиды foxmi и вакцины, содержащие их
JP2010519176A5 (enExample)
RU2009118432A (ru) Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1
RU2010154081A (ru) Эпитопные пептиды iqgap3 вакцины, содержащие их
JP2010523471A5 (enExample)
HRP20141233T1 (hr) PEPTIDNA CJEPIVA DOBIVENA IZ EphA4
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
JP2012517799A5 (enExample)
RU2010154101A (ru) Пептиды эпитопов mybl2 и содержащие их вакцины
RU2010110545A (ru) Cdh3-пептид и включающее его лекарственное средство
RU2012127358A (ru) Олигопептиды imp-3 и содержащие их вакцины
RU2011110376A (ru) Эпитопные пептиды hig2 и urlc10 и содержание их вакцины
RU2009129531A (ru) Вакцины на основе пептида foxp3
JP2011529683A5 (enExample)
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
JP2010514669A5 (enExample)
RU2013158399A (ru) Пептиды sema5b и содержащие их вакцины
RU2010126154A (ru) Эпитопные пептиды stat3
RU2012147590A (ru) Пептиды cdca5 и содержащие их вакцины
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140714